Based on available evidence, EMA advised against using daclizumab in patients with pre-existing hepatic disease or hepatic impairment and in patients with autoimmune diseases other than MS, and they urge caution when using the drug in combination with drugs that can damage the liver.Reference Brooks 100 In Canada, daclizumab was approved as second- or third-line option
Mushenkova NV, Bezsonov EE, Orekhova VA, Popkova TV, Starodubova AV, Orekhov AN
We will cover the biological mechanisms behind this side effect, explore how common it is, and offer practical advice on how to prevent and manage it
This activation is achieved via inhibition of the Nrf2 repressor Keap-1
For example, a 4mg dose from a 10mg vial reconstituted with 2mL BAC water equals 80 units